Brain Tumor
Epigenetic downregulation of CTMP transcription common in glioblastomas
Published in Gene Therapy Weekly, May 20th, 2004
"The carboxyl-terminal modulator protein (CTMP) has been identified as a negative regulator of protein kinase B/Akt. Aberrant Akt signaling is frequently observed in glioblastomas, the most common and most malignant glial brain tumors. Because loss of CTMP function and/or expression may remove the inhibitory effects on Akt and promote tumorigenesis," 93 primary glioblastomas and nine glioblastoma cell lines" were studied "for CTMP deletion, mutation, promoter hypermethylation, and mRNA expression," wrote scientists in the Journal of the National Cancer Institute.
"None...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-05-20)
More Articles from Gene Therapy Weekly
- Adverse Drug Effects
Long-term studies show transduced stem cells do not cause leukemia - Cancer Prevention
Upregulated heat shock protein 70 protects against tumor growth in mice - Diagnostics
A new semiquantitative assay explores the angiogenic potential of genes - Gene Suppression
Interleukin-12 gene therapy changes gene expression to block cancer growth - Immunology
Interleukin-12 gene therapy and 4-1BB costimulation drive melanoma eradication - Antitumor Effects
Magnaese superoxide dismutase mutant has potent antitumor effects - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
